Good spotting, but my take on 129 xenon is that it is suggested as an imaging agent in MRI to look at lung function, which is what CYC claim they can do with technegas and SPECT - but this is all proposed as a future use of technegas and they are doing research now to confirm.
But the big issue is that the business model for CYC in the US is about using tenchnegas to diagnose pulmonary embolus, which requires a quick and reliable imaging modality. Currently in the US they use CTPA (CT pulmonary angiography). For 129 xenon to gain traction for this indication it needs to be able to be used in PE diagnosis - but it doesn’t do that at all. It only looks at lung structure (as far as I can see, but that is the question that needs to be asked).
So yes, 129 Xenon could be a competitor to tenchegas when it comes to assessing COPD, but that is still blue sky for CYC and not factored into what they are doing in the US for PE now. Remember too that MRI is much more expensive than technegas and SPECT.
CYC Price at posting:
$1.50 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)